Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD
Mayra Shanley(The University of Texas MD Anderson Cancer Center), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center)
Cited by 79
Related Papers
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
|Nature Medicine|2024|452
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
|Blood|2020|284
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
|Frontiers in Immunology|2015|267
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells
|Journal of Clinical Investigation|2021|245
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|236